Rare diseases create a problem that traditional drug development was never designed to solve perfectly. A conventional clinical program works best when researchers can recruit large numbers of patients, study a disease with a well-understood natural history, use validated endpoints, and compare treatment groups with enough statistical power to reach clear conclusions.
Many rare diseases offer none of those advantages.
Some affect only a few hundred people worldwide. Patients may live across multiple countries. The disease may progress differently from one person to another. Researchers may lack validated biomarkers or accepted clinical endpoints. In some conditions, even the natural history remains poorly understood.
On October 14, the FDA launched its new Rare Disease Framework Initiative to address that reality. Rather than expecting every rare-disease program to fit neatly into the same development model, the agency wants a more consistent approach that considers the disease itself, the size and needs of the patient population, the type of therapy being developed, and the evidence researchers can realistically generate.
The initiative is regulatory policy, but the larger story is about where medicine is heading.
Rare-disease therapies, gene therapies, precision medicine, biomarker-driven treatment, and highly individualized therapies are expanding the definition of what medication care looks like. As that happens, pharmacists may find growing opportunities around the infrastructure required to move those therapies from development to the right patient.
Rare diseases expose the limits of the traditional model
FDA defines a rare disease in the United States as one affecting fewer than 200,000 people. However, many conditions affect far fewer patients. According to the agency’s new white paper, about 30 million Americans live with a rare disease across an estimated 7,000 to 10,000 conditions. Yet only about 5% of recognized rare diseases had an FDA-approved treatment as of 2025.
Developing treatments for these diseases can be unusually difficult. Small populations make recruitment slow. Geographic dispersion adds another barrier. Researchers may have little natural-history data to guide trial design. In addition, meaningful endpoints may not exist yet, while genetic and clinical differences among patients can make interpretation more difficult.
FDA’s new initiative aims to make the regulatory approach more consistently fit for those circumstances. The agency says its advice and decisions should reflect what evidence is reasonably attainable for the specific disease and product while still meeting statutory standards for safety and effectiveness.
That distinction matters. FDA is not announcing weaker standards for rare-disease drugs. Instead, it is asking whether the path used to generate convincing evidence should look different when the scientific reality is different.
The framework reaches far beyond clinical-trial design
One reason pharmacists should pay attention is the scope of the initiative.
FDA says the framework will span the development process from pre-IND discussions through post-approval obligations. It also includes chemistry, manufacturing, and controls, or CMC, as well as coordination between the agency’s drug and biologics centers.
The agency plans to examine several areas at once. It wants more consistent use of external disease expertise. It wants to integrate patients earlier. It plans to consider risk-based approaches to CMC review and inspections. FDA also wants to support new trial designs, innovative statistical methods, and newer scientific approaches when they fit the disease and development program.
That matters because rare-disease treatment often requires more than proving that a molecule works.
For a traditional oral medication used by millions of people, the healthcare system has decades of experience moving products through manufacturing, distribution, prescribing, dispensing, and monitoring.
An advanced therapy for several hundred patients can require an entirely different infrastructure. The organization may need genetic confirmation of the diagnosis, specialized treatment centers, unique storage and handling, payer approval, limited distribution, extensive patient education, coordinated monitoring, and long-term follow-up.
The therapy may be rare. The work surrounding it is not simple.
FDA also wants the patient involved earlier
The new framework specifically calls for the patient voice to enter development earlier and at defined milestones.
That is especially important in rare disease, where regulators and researchers may have limited experience with the condition compared with the families living with it every day. Patients can help describe which symptoms affect life most, what level of treatment risk they would accept, and which changes would actually represent meaningful improvement.
On October 16, FDA and the Reagan-Udall Foundation held a separate meeting focused on the patient voice in rare-disease medical product development. The discussion examined where patients currently contribute across the development timeline and where product developers and regulators could involve them more effectively.
This may also affect how evidence gets created.
A laboratory measurement can improve without producing a change patients notice. Conversely, a therapy may improve a function that matters enormously to patients but is difficult to capture with traditional endpoints.
Rare-disease development therefore increasingly requires teams that can connect biology, regulatory science, clinical evidence, patient experience, and real-world treatment.
That is a much more interdisciplinary environment.
Medicine is becoming more individualized, and the system around it is becoming more complex
Rare disease is part of a broader shift.
Drug development is moving toward more precise definitions of who should receive a therapy. Genetic variants can determine eligibility. Biomarkers can identify smaller populations. Cell and gene therapies can target mechanisms that conventional drugs could not reach. Personalized medicine can divide what once looked like one disease into several biologically distinct groups.
The more precise treatment becomes, the more coordination it may require.
A patient receiving a complex therapy may need confirmation of the molecular diagnosis before treatment begins. The health plan may require a detailed authorization. A specialty or limited-distribution pharmacy may become involved. The manufacturer may offer financial or patient-support services. Treatment could require a certified center, special preparation, or unusual storage. Monitoring may continue for years.
Someone has to understand how all of those pieces fit together.
That does not turn every pharmacist into a rare-disease specialist. It does create a growing need for professionals who understand both the therapy and the healthcare machinery required to deliver it.
This is where the pharmacist’s role can expand.
The future pharmacist may increasingly become a therapy navigator
Pharmacists have traditionally been described as medication experts. That remains accurate, but advanced therapies can make medication expertise much broader.
For a complex rare-disease therapy, knowing the mechanism and adverse effects may be only the beginning. The care team may also need help with eligibility criteria, administration requirements, drug interactions, monitoring, access, distribution, payer requirements, adherence, caregiver education, and long-term safety.
ASHP’s Center for Next-Generation Therapeutics reflects how seriously the profession is beginning to take this shift. The center covers cell and gene therapies, personalized medicine, theranostics, rare-disease therapies, and other high-cost or complex treatments. Its resources focus not only on clinical issues but also on operational, financial, safety, and ethical considerations.
That combination is important.
A pharmacist working around next-generation therapies may spend less time thinking about how efficiently a prescription can be dispensed and more time helping a health system determine whether it can safely deliver the therapy at all.
Another pharmacist may work in specialty access and coordinate benefits, distribution, and financial assistance. Someone else may support a gene-therapy program, manage investigational products, work in medical affairs, help design patient-support programs, or contribute to regulatory and clinical-development teams.
The common thread is not dispensing. It is helping a complicated therapy successfully move through a complicated system.
There is already evidence that pharmacists contribute across rare-disease care
This is not only a future possibility.
A 2026 scoping review examined 68 studies involving pharmacist services in rare diseases. The most frequently reported activities included patient and caregiver education, prescription monitoring, and medication review. The authors found that the available studies suggest pharmacist interventions may improve treatment access, adherence, medication safety, and some healthcare outcomes. They also emphasized that more research is needed to define the pharmacist’s impact more clearly.
That review is useful because it shows how broad the role can become.
Rare-disease care often involves patients and caregivers who must become highly knowledgeable about a condition that many healthcare professionals encounter rarely. Treatment may involve complicated dosing, monitoring, access requirements, and safety concerns. In that environment, education and medication coordination are not minor services.
They can become part of the infrastructure that keeps therapy working.
As more rare-disease products reach the market, health systems and specialty organizations will need to build that infrastructure repeatedly across new disease states.
For pharmacists, that creates a career signal.
The opportunity is larger than rare-disease pharmacy
A pharmacist interested in this area should not search only for jobs titled “rare disease pharmacist.”
The career landscape is much wider.
Rare-disease development can intersect with regulatory affairs, clinical development, medical affairs, specialty pharmacy, patient access, health economics, clinical operations, investigational drug services, pharmacovigilance, gene-therapy operations, quality, reimbursement, and patient-support programs.
Some of those roles strongly value a PharmD. Others may prefer different scientific or operational backgrounds. Many will require experience pharmacists do not automatically gain from traditional practice.
That is not a reason to ignore them.
It is a reason to study the functions first.
For example, a pharmacist interested in cell and gene therapy may discover that employers value experience with advanced-therapy operations, specialty distribution, sterile handling, institutional readiness, or treatment-center coordination.
Someone interested in patient access may see repeated requirements around insurance navigation, specialty benefits, reimbursement, manufacturer assistance, and case management.
A regulatory role may emphasize evidence generation, clinical development, CMC, and communication with FDA.
Once the work becomes visible, the career path becomes easier to understand.
Do not start by asking whether you qualify
This week, choose one area: rare-disease pharmacy, cell and gene therapy, orphan drugs, specialty pharmacy, patient access, or gene-therapy operations.
Then search actual job descriptions.
Do not begin by deciding whether you qualify. That often ends the research too early.
Instead, read five to ten roles and look for patterns. Which companies are hiring? What departments own the work? Which skills appear repeatedly? What type of experience do they want? Which responsibilities rely on pharmacy knowledge, and which would require new training?
Then compare those requirements with your current experience.
Perhaps you already have specialty-pharmacy exposure but need more knowledge of rare-disease access. Maybe you understand medication operations but have never worked around gene therapy. You might have strong clinical knowledge but need experience with project management, reimbursement, or patient-support programs.
That gap becomes your roadmap.
This approach is far more useful than collecting random certifications and hoping one creates a career.
Rare disease is a preview of where medicine may be going
The FDA’s new framework is still in development. The agency will gather public input, hold additional roundtables, review existing policies and guidance, and consider future regulatory or organizational changes. FDA has also scheduled an October 28 public meeting dedicated to the initiative.
So this is not a new rule that suddenly changes rare-disease approvals.
It is a signal that the regulatory system sees a need to adapt as the science becomes more specialized.
That should matter to pharmacists.
For much of the profession’s history, the medication was a relatively standardized product moving through a familiar system. Increasingly, some of the most important therapies will reach tiny populations, depend on molecular diagnosis, cost enormous amounts, require specialized distribution, and generate evidence in ways that look different from traditional development.
In that world, the pharmacy challenge changes.
The question is no longer only whether the pharmacist knows the drug.
It is whether someone can help connect the right patient, the right evidence, the right therapy, the right access pathway, the right distribution channel, and the right monitoring plan.
That is why rare disease deserves attention even from pharmacists who never expect to specialize in it.
It offers a preview of a healthcare system where treatments become more precise while the infrastructure around them becomes more complex.
And when complexity increases, people who know how to connect the pieces become more valuable.
For pharmacists willing to understand that system early, the next generation of therapies may also create a new generation of career opportunities.
Resources & Citations
- U.S. Food and Drug Administration. “FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development.” October 14, 2026. Primary announcement of the initiative, including its focus on tailored evidence, patient input, external expertise, risk-based regulatory approaches, and innovative clinical-trial and statistical methods.
- U.S. Food and Drug Administration. “A New Framework for Rare Disease Review.” October 2026. FDA white paper outlining the rare-disease development challenge, the scale of unmet need, the intended scope of the framework from pre-IND through post-approval obligations, and potential changes involving guidance, regulations, training, CMC, endpoints, trial design, statistics, and patient engagement.
- U.S. Food and Drug Administration. “Rare Disease Framework.” October 2026. FDA overview of the initiative’s expected goals, including more predictable decision-making, integration of the patient voice, external expertise, risk-based review, and use of novel science and trial methods.
- U.S. Food and Drug Administration and Reagan-Udall Foundation. “Patient Voice in Rare Disease Medical Product Development.” October 16, 2026. FDA meeting focused on how patient perspectives currently influence rare-disease product development and where developers and regulators can integrate them more effectively.
- American Society of Health-System Pharmacists. “ASHP Center for Next-Generation Therapeutics.” Current resource center covering cell and gene therapy, personalized medicine, theranostics, rare-disease therapies, and other high-cost and complex treatments, with attention to clinical, operational, financial, ethical, and safety issues for pharmacy practice.
- Cunico C, Fuchina MN, Rover MRM, Santana RS, Leite SN. “Facing the Challenges of Treating Rare Diseases: A Scoping Review of the Role of Pharmacists.” International Journal of Pharmacy Practice. Published online June 7, 2026. The review included 68 studies and found pharmacist activities most commonly involved education and counseling, prescription monitoring, and medication review. The authors reported potential benefits while noting the need for additional research.